glp-1 suicidal ideation Frontiers New data provide 'much-needed reassurance'

Instead, a spokesperson asserted that the Food and Drug Administration "supports expanded access programs that can provide patients with serious or life-threatening conditions access to investigational treatments when no comparable or satisfying approved therapies are available." "Each request is reviewed on a case-by-case basis based on the clinical circumstances and applicable statutory and regulatory requirements," the spokesperson added

In Russia, this peptide is used as a common alternative for drug therapy for children with ADHD

[Abstract]2025 Feb 28;16(1):2036

Therapeutic targets for treating fibrotic kidney diseases

A.TsonisP

Despite the encouraging findings, both research teams emphasize that the evidence remains preliminary